Background: The lack of Treponema pallidum-specific antigens with highly accurate diagnosis makes the diagnosis of syphilis challenging. Methods: A soluble recombinant version of a new diagnostic protein Tp0663 has been produced. The serodiagnostic potential of this protein was assessed by screening 3326 serum samples simultaneously evaluated by rapid plasma reagin and T. pallidum particle agglutination tests. Kappa (k) coefficients were used to compare the concordance between clinical diagnosis and the Tp0663-based ELISA or the ARCHITECT Syphilis TP chemiluminescent immunoassay (Abbott GmbH and Co. KG). Results: Using the results of clinical diagnosis as the gold standard, the sensitivity and specificity of Tp0663 were found to be 98.83% (95% confidence interval (CI) 96.61-99.60%) and 100% (95% CI 99.88-100%), respectively. In comparison, the ARCHITECT Syphilis TP assay was found to have a lower sensitivity (97.27%, 95% CI 94.46-98.67%) and specificity (99.61%, 95% CI 99.32-99.78%). In particular, the ARCHITECT Syphilis TP exhibited a false-positive rate of 0.39%. Moreover, the ELISA was in perfect agreement with the gold standard, with a k value of 0.99, comparable to that of ARCHITECT Syphilis TP (0.96). Conclusion: These results identified Tp0663 as a novel serodiagnostic candidate with great potential for developing novel tests for the diagnosis of syphilis.
Introduction
Syphilis is a perplexing infection caused by the spirochete Treponema pallidum, which is transmitted primarily through sexual contact. It progresses through multiple clinical stages, with typical clinical features including the hard chancre during primary syphilis, followed by a generalized rash and lymphadenopathy during secondary syphilis. Upon resolution of this stage of syphilis, the infection enters an asymptomatic, latent phase lasting from months to decades. Diverse and chronic symptoms emerge during tertiary syphilis, including neurosyphilis, cardiovascular involvement, and gummas. 1 The laboratory diagnosis of syphilis is dependent on the use of a multitude of serological tests due to the fact that T. pallidum cannot be cultured in vitro; 2, 3 this is in contrast to most bacterial diseases, for which a definite diagnosis can be made by direct detection of the pathogen. The common serological tests for the diagnosis of syphilis are divided into two categories: non-treponemal tests and treponemal tests. The non-treponemal tests, such as the rapid plasma reagin (RPR) test and the venereal disease research laboratory (VDRL) test, are used mainly to determine serological activity and to monitor the therapeutic effect. Despite the advantages of these tests, which are widely available, inexpensive, and simple to perform, the results require further confirmatory screening for the detection of Treponema-specific antibodies. The treponemal tests, such as the T. pallidum particle agglutination (TPPA) assay, the T. pallidum hemagglutination (TPHA) assay, and the fluorescent treponemal antibody absorption (FTA-ABS) test, are used to detect the specific treponemal antibodies. Nevertheless, these tests are labor-intensive and highly operator-dependent. Furthermore, they exhibit poor sensitivities in the detection of early syphilis. 4 In recent years, automated enzyme immunoassays (EIAs) and chemiluminescence immunoassays (CIAs) have also been developed for the serodiagnosis of syphilis. These assays, using one or more of the recombinant T. pallidum proteins TpN15 (Tp0171), TpN17 (Tp0435), TpN44.5 (TmpA, Tp0768), and TpN47 (Tp0574), 5, 6 have gained the interest of researchers in the field of syphilis diagnosis because they are objective, reproducible, automated, and computerized. 7 More importantly, these tests have led some large laboratories in the USA to screen patients with the reverse algorithm, which begins with a treponemal test; reactive tests are followed by a quantitative non-treponemal test and discordant samples must be rescreened with a second and different treponemal test. 8, 9 Although these proteins have been used in the serodiagnosis of syphilis, there is no general agreement as to which protein antigens are best in terms of serodiagnostic performance, and surface-exposed proteins may have superior sensitivity to the currently used proteins due to their immediate exposure to the immune system. Therefore, it is of great importance to evaluate new recombinant antigens with highly accurate diagnosis for use in serological testing for syphilis.
The purpose of this study was to analyze the diagnostic potential of recombinant antigen Tp0663, a 28-kDa T. pallidum subsp. pallidum outer membrane protein that has previously been reported in several works as being reactive with sera from syphilis patients. 10, 11 The sensitivity and specificity of the recombinant antigen were evaluated using sera collected from 3326 individuals, and subsequently compared with the recently launched ARCHI-TECT Syphilis TP test, a CIA that exhibits excellent ability to automate testing in high-throughput instrumentations. The results showed that the T. pallidum protein Tp0663-based immunoglobulin G (IgG) ELISA exhibited higher overall sensitivity and specificity than the ARCHITECT Syphilis TP. Therefore, Tp0663 represents a promising new candidate that could potentially be incorporated into automated diagnostic tests for syphilis.
Materials and methods

Genomic DNA of Treponema pallidum subsp. pallidum Nichols strain
The T. pallidum subsp. pallidum Nichols strain used in this study was a generous gift from Tianci Yang (Zhongshan Hospital, Medical College of Xiamen University, Xiamen, China) and was propagated in adult New Zealand white rabbits, as described elsewhere. 12, 13 All animal experiments were approved by the Institutional Review Committee of the University of South China. The serological detection of syphilis in each sample (from 3326 subjects) was performed using the RPR and TPPA tests, which were performed in accordance with the manufacturers' instructions, after duplicate tests were excluded. All serological tests were performed on the same serum sample, and the results of the two tests were reported simultaneously. The subjects in this study included 948 individuals undergoing routine health examinations, 1358 outpatients, and 1020 inpatients. These subjects underwent syphilis detection for screening (if asymptomatic), for diagnosis (if symptomatic), or to monitor the effects of therapy. In accordance with the staging criteria described in the literature, 14 the clinical diagnosis of syphilis was determined by combining serological tests and disease history (including clinical signs and symptoms, and/or the patient's sexual history). Primary syphilis is generally characterized by painless chancre and serous fluids from the lesion, usually coupled with regional lymphadenopathy; there has generally been sexual contact with a person with syphilis, and laboratory confirmation involves dark-field examination and/or positive results of both RPR and TPPA to confirm the diagnosis of syphilis. Secondary syphilis is often characterized by a generalized rash, mucocutaneous lesions, and lymphadenopathy; there is generally a history of sexual exposure to a person with syphilis or primary syphilis, and reactive serological tests (RPR and TPPA) are used to confirm the diagnosis. Latent syphilis is asymptomatic, with a possible history of infection supported by a reactive RPR or TPPA result. An onset of infection within the last 2 years is referred to as early latent syphilis and a duration of latent syphilis >2 years is defined as late latent syphilis. Tertiary syphilis is considered as syphilis presenting with typical clinical symptoms, such as gummatous lesions, neuropsychiatric illness, and cardiovascular involvement, and a history of primary, secondary, or latent syphilis, in addition to clinical confirmation by positive results of both RPR and TPPA. The diagnostic tests used to confirm the serum samples are listed in Table 1 .
Serum samples
Recombinant protein expression and purification
The tp0663 gene was amplified by PCR using the forward primer 5 0 -CCGGAATTCATGAAACAGGGCTGTTTTAT 3 0 (EcoRI) and the reverse primer 5 0 -CCCAAGCTTTCATTTGCCGCTCTCTCCTT 3 0 (Hin-dIII) and then cloned into pET-28a expression vector. This construct was transformed into Escherichia coli BL21 (DE3) cells and the positive clone was confirmed by DNA sequencing. Protein expression was induced overnight at 30 8C with 0.1 mM isopropylb-D-thiogalactopyranoside (IPTG). Bacteria were harvested and lysed in a buffer containing 50 mM Tris-HCl (pH 7.8), 300 mM NaCl, 10 mM imidazole, 20% glycerol, and 1% Triton X-100. Histagged protein was purified by affinity chromatography using Ni-NTA beads (Qiagen, Inc., Hilden, Germany). The concentration of the recombinant protein was estimated using a bicinchoninic acid protein assay kit (Pierce, Rockford, USA).
Western blotting analysis
Recombinant protein Tp0663 was electrophoresed in a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and then transferred to a nitrocellulose membrane (Merck Millipore, Darmstadt, Germany). After blocking at room temperature for 2 h with phosphate-buffered saline (PBS) containing 5% nonfat milk and 0.05% Tween 20 (PBSTM), membranes were incubated overnight at 4 8C with human sera (1:500), rabbit sera (1:400), or anti-His-tagged monoclonal antibody (1:1000). Before being incubated separately with corresponding secondary antibodies at 37 8C for 1 h, membranes were washed extensively with PBS containing 0.05% Tween 20 (PBST) (the dilutions of secondary antibodies were as follows: horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Abcam, Cambridgeshire, UK), 1:8000; HRP-conjugated goat antirabbit IgG (Abcam), 1:12 000; HRP-conjugated goat anti-mouse IgG (Millipore, Darmstadt, Germany), 1:10 000). Finally, chemiluminescent detection was performed using G:BOX Chemi XXX9 (Syngene, Cambridge, UK) after washing five times with PBST.
ELISA
Recombinant protein Tp0663 was diluted in carbonate buffer (0.1 M, pH 9.6), then 96-well plates (Corning Costar, New York, USA) were coated with 100 ml per well overnight at 4 8C. With intervening washes, the plates were blocked for 2 h at room temperature with 200 ml PBSTM. Serum samples were diluted 1:100 with PBSTM, and 100 ml was added to each well. After incubation for 2 h at 37 8C, the plates were washed extensively with PBST. HRP-conjugated goat anti-human IgG was used at a dilution of 1:10 000, and then 100 ml was added to each well. The mixture was incubated for 1 h at 37 8C. Plates were developed by adding 100 ml tetramethylbenzidine substrate to each well and incubated at room temperature for 30 min. The reaction was stopped by the addition of 100 ml of 1 M sulfuric acid. The absorbance was read at 450 nm. Each sample was assayed in duplicate. The mean optical density value for the uninfected control sera determined by clinical diagnosis plus two times the standard deviation was considered as the cutoff value to determine positivity in each sample. The cutoff value of the ELISA was 0.4121. Absorbance values less than or equal to the cutoff value were determined to be negative, while those greater than the cutoff value were defined as positive.
ARCHITECT Syphilis TP
ARCHITECT Syphilis TP is a two-step immunoassay performed on an fully automated system Architect i2000SR analyzer (Abbott, Chicago, USA), which utilizes recombinant treponemal antigens (TpN15, TpN17, and TpN47) to qualitatively detect the IgG and IgM antibodies to T. pallidum in human serum or plasma. This test has shown perfect performance when compared to the TPPA 15 and could be used as a reliable test for the detection of syphilis. 16, 17 The results of the chemiluminescent reaction are measured in relative light units (RLUs), with an RLU value of <1.00 indicating a negative result and an RLU value of 1.00 indicating a positive result. The level of RLUs is directly related to the amount of anti-T. pallidum antibodies in the serum. All serum samples described above, including positives from different stages of infection and nonreactive samples, were screened in duplicate according to the manufacturer's instructions. 
Results
Clinical diagnosis of syphilis patients
In this study, RPR and TPPA tests were performed on samples from 3326 subjects between February 2015 and May 2015. Syphilis was diagnosed clinically by combining serodiagnosis and personal history (including the patient's sexual history and clinical characteristics). Ultimately, 256 subjects were diagnosed with syphilis and 632 subjects were found to be healthy by clinicians. Thus, the prevalence of syphilis was 7.70% (256 of 3326 patients).
The clinical data for all of the subjects are given in Table 2 .
Recombinant protein expression, purification, and identification
The tp0663 gene was successfully amplified by PCR ( Figure 1) . The optimal expression of the His-tagged protein was observed with induction of 0.1 mM IPTG overnight at 30 8C. The soluble recombinant protein was determined through SDS-PAGE analysis to have an estimated purity of >95% ( Figure 2 ). The antigenicity of Tp0663 was confirmed using anti-His monoclonal antibody, rabbit sera infected with T. pallidum Nichols strain (n = 2), and serum samples from syphilis patients (n = 18) ( Figure 3 ). These sera from the syphilis patients, including two samples from patients with primary syphilis, three from patients with secondary syphilis, two from patients with early latent syphilis, seven from patients with late latent syphilis, and four from patients with tertiary syphilis, showed reactivity to recombinant protein Tp0663. However, no reactivity between Tp0663 and normal human sera (n = 5) or serum samples from patients infected with hepatitis B virus (n = 4), hepatitis C virus (n = 1), Helicobacter pylori (n = 1), and cytomegalovirus (n = 1) was observed in this study (Figure 4) . These findings showed that the recombinant antigen exhibited 100% sensitivity and 100% specificity in the Western blotting analysis.
Evaluation of the diagnostic performances of the two syphilis serological tests compared with the gold standard
With the clinical diagnosis of syphilis as the gold standard, the serodiagnostic potential of the two syphilis serological tests was evaluated in this study. The results indicated that with the ARCHITECT Syphilis TP, 261 of the 3326 subjects would have been diagnosed with syphilis, whereas seven subjects determined to be syphilis patients by clinical diagnosis would not have been diagnosed. Among these syphilis patients, 12 were confirmed to be healthy by clinical diagnosis. The false-positive rate was 0.39% (12 of 3070 subjects) and the missed diagnosis rate was 2.73% (7 of 256 subjects). Furthermore, the sensitivity of the ARCHITECT Syphilis TP was 97.27% (95% confidence interval (CI) 94.46-98.67%) ( Table 3 ). In addition, the seven cases of missed diagnosis were analyzed further. It was found that there was one case of primary syphilis, three of late latent syphilis, and three of tertiary syphilis. Moreover, among these seven cases, three patients were being diagnosed with syphilis for the first time.
In comparison, using the ARCHITECT Syphilis TP and the Tp0663-based ELISA, 249 and 253 subjects, respectively, had a reactive serodiagnosis. The sensitivity levels of the ARCHITECT Syphilis TP and the ELISA were 97.27% (95% CI 94.46-98.67%) and 98.83% (95% CI 96.61-99.60%), respectively. In addition, the specificities of the ARCHITECT Syphilis TP and the ELISA were 96.61% (95% CI 99.32-99.78%) and 100% (95% CI 99.88-100%), respectively ( Table 3 ). Both the ARCHITECT Syphilis TP and the antigen exhibited strong discriminatory power in the serodiagnosis of syphilis. 
Comparison of the two serodiagnosis tests at different stages of syphilis
The 256 cases of syphilis were further classified into different stages of syphilis to evaluate the two serological tests at the different stages (Table 4 ). It was found that the ARCHITECT Syphilis TP had high sensitivity not only for primary syphilis (90.91%) and secondary syphilis (100%), but also for tertiary syphilis (94.64%). The ELISA exhibited sensitivities of 100%, 97.14%, and 98.21% for primary, secondary, and tertiary syphilis, respectively.
Direct comparison of the concordance between clinical diagnosis and the Treponema pallidum recombinant antigen Tp0663-based ELISA or the ARCHITECT Syphilis TP
For all of the samples, the agreement and k values of the ELISA and the ARCHITECT Syphilis TP were compared with clinical diagnosis (gold standard). The ELISA showed 99.91% (95% CI 99.88-99.94%) agreement and a k value of 0.99, and the ARCHITECT Syphilis TP exhibited 99.43% (95% CI 99.36-99.50%) agreement and a k value of 0.96 ( Table 5 ). The results indicated that the two serological tests had high consistency with clinical diagnosis.
Discussion
The identification and characterization of new immunodominant antigens of T. pallidum is central to the improvement of the current laboratory diagnosis of syphilis, a disease that has resurged worldwide in recent years, including in China. [19] [20] [21] A variety of T. pallidum proteins, including TpN44.5, TpN15, TpN17, TpN47, Tp0453, Tp92 (Tp0326), and TpF1 (Tp1038), 5, 6, [22] [23] [24] have been tested in recent decades. Some of these antigens have been used in commercial tests that exhibit high sensitivity and specificity. However, not all patients suffering from syphilis are detected with the use of these antigens, thus more sensitive and specific recombinant T. pallidum antigens would be useful for screening syphilis patients.
In this study, Tp0663, a 28-kDa T. pallidum subsp. pallidum outer membrane protein that has surface-exposed epitopes, 25 was expressed as a recombinant version in E. coli; this may allow the protein to be produced economically and in large quantities in vitro due to the inherent advantage in the preparation of recombinant antigen compared to the extraction of crude T. pallidum antigen. 22 The molecular weight of the expressed recombinant protein was a little larger than that predicted, possibly due to the His tag at the N terminus. Consistent with the works performed by McKevitt et al. 10 and Brinkman et al., 11 the recombinant protein identified by SDS-PAGE was found to be reactive with sera from rabbits infected with the T. pallidum Nichols strain and with sera from syphilis patients. However, no reactivity was observed between recombinant protein Tp0663 and uninfected controls and potentially cross-reactive serum samples, showing the recombinant antigen to be a highly sensitive and specific candidate for the serodiagnosis of syphilis in Western blotting analysis.
The direct comparison of the diagnostic performances of the recombinant T. pallidum antigen Tp0663 and the ARCHITECT Syphilis TP tests is one focus of this study. Using the clinical diagnostic results as the gold standard, the ARCHITECT Syphilis TP exhibited a sensitivity of 97.27% and a specificity of 99.61%, while Tp0663 showed a stronger discriminatory power for the serodiagnosis of syphilis (98.83% sensitivity and 100% specificity). Most surveillance has focused on early syphilis cases, which is the best indicator of the infection and more likely to result in the timely treatment of patients. Thus, the serodiagnosis by the two serological tests was further analyzed at the different stages of syphilis, and especially in early syphilis. It was found that Tp0663 (2), early latent syphilis (3), late latent syphilis (4), tertiary syphilis (5), hepatitis B virus (6), hepatitis C virus (7) , cytomegalovirus (8) , and human immunodeficiency virus (9) using HRP-conjugated goat anti-human IgG. exhibited higher sensitivity and specificity than the ARCHITECT Syphilis TP, although both tests showed high diagnostic significance in early syphilis, as well as in late syphilis. In particular, 12 false-positives would have resulted from the screening of all of the serum samples with the ARCHITECT Syphilis TP. This may be explained by the fact that the ELISA uses outer membrane protein Tp0663 as an antigen, which is thought to be exposed continuously to the immune system and to continually stimulate robust antibody responses, thus having a theoretical advantage in the detection of specific antibodies in individuals with syphilis. 25 In contrast, the ARCHITECT Syphilis TP uses lipoproteins TpN15, TpN17, and TpN47 as the coated antigens; these are thought to be able to induce a strong immune response by activating antigenpresenting cells through toll-like receptor 2. 26, 27 Some of these lipoprotein antigens are believed to be concealed in the periplasm of the bacterium, 28 although they were at first considered to reside on the surface of this pathogen. Moreover, the high overall percentage of agreement and corresponding k values found in this study indicated that the ELISA was in perfect agreement with clinical diagnosis. Based on these results, recombinant antigen Tp0663 may represent an effective candidate for the seroscreening of syphilis. It should be emphasized that Tp0663 may be compatible with commercially available diagnostic tests, such as CIAs and EIAs, since the protein is expressed in a soluble form. Currently, most automated tests used for the serodiagnosis of syphilis utilize multiple recombinant treponemal antigens. This has the potential to confound results because patients may have different serological responses to these antigens regardless of the presence of infection. 29 In addition, the development of a test using a single recombinant treponemal protein could cut the costs associated with the preparation of multiple antigens. Furthermore, Tp0663 does show the potential for detecting syphilis patients with high accuracy, which may eliminate the need to perform a variety of tests and thus decrease the medical burden for the patient. In summary, these results suggest that Tp0663 is a promising candidate for incorporation into many test formats for the detection of syphilis.
A limitation of this study is that it was performed in a distinct geographical location. The subjects tested were all recruited in Hunan, China, which is an area with a relatively high prevalence of syphilis, and samples were not collected from other areas with a lower prevalence. Thus, this study only reflects the characteristics of areas with a high prevalence of syphilis. Similar studies in lowerprevalence regions will be performed in the future. Another limitation is the potential misclassification of patients due to the possible incorrect documentation and inadequate documentation in the medical records. Some patients used false information to protect their privacy (including name, age, history of infection, and inappropriate treatment they had received), which made it difficult to diagnose their syphilis infection and give them timely and effective treatment.
In conclusion, a new serodiagnostic candidate -Tp0663 -has been identified, which is extremely sensitive (98.83%) and specific (100%) for the detection of all stages of the infection. In a direct comparison, the serodiagnostic performance of the recombinant protein even exceeded that of the commercially available ARCHITECT Syphilis TP. Therefore, recombinant antigen Tp0663 may represent a new candidate for the detection of syphilis, considering the potential for automation, high throughput, and its valuable diagnostic performance.
